Page last updated: 2024-12-08

cysteinylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cysteinylglycine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not in Chemlne 7/13/83 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-cysteinylglycine : A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID439498
CHEMBL ID371579
CHEBI ID4047
SCHEMBL ID213626
MeSH IDM0091689

Synonyms (42)

Synonym
brn 1724689
glycine, n-l-cysteinyl-
glycine, n-cysteinyl
ccris 2905
19246-18-5
cys-gly ,
l-cysteinylglycine
C01419
l-cysteinyl-glycine
n-l-cysteinylglycine
CHEBI:4047 ,
cysteinylglycine
1F802DB1-4F4D-4B9F-9C68-CA4998E23132
cysteinyl-glycine
bdbm50169213
CHEMBL371579 ,
2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]acetic acid
2-[[(2r)-2-azaniumyl-3-sulfanylpropanoyl]amino]acetate
AKOS006272654
4-04-00-03158 (beilstein handbook reference)
384644sz9t ,
unii-384644sz9t
glycine, l-cysteinyl-
glycine, n-cysteinyl-
dipeptide-4
quintescine
dipeptide-4 [inci]
SCHEMBL213626
ZUKPVRWZDMRIEO-VKHMYHEASA-N
mfcd00055567
h-cys-gly-oh
n-cysteinyl glycine
n-l-cysteinyl-glycine
n-cysteinyl-glycine
DTXSID10864877
HY-113110
(r)-2-(2-amino-3-mercaptopropanamido)acetic acid
Q27106297
CS-0059601
BS-52915
2-[(2r)-2-amino-3-sulfanylpropanamido]acetic acid
EN300-6479304

Research Excerpts

Overview

Cysteinylglycine is a pro-oxidant metabolite of glutathione. It is a precursor of cysteine.

ExcerptReferenceRelevance
"Cysteinylglycine is a pro-oxidant metabolite of glutathione and a precursor of cysteine."( Prospective study of serum cysteine and cysteinylglycine and cancer of the head and neck, esophagus, and stomach in a cohort of male smokers.
Abnet, CC; Albanes, D; Diaw, L; Freedman, ND; Männistö, S; Miranti, EH; Murphy, G; Selhub, J; Stolzenberg-Solomon, RZ; Taylor, PR; Weinstein, SJ, 2016
)
1.42
"Cysteinylglycine hydrolysis is a step in the metabolism of glutathione and glutathione S-conjugates. "( Identification of cytosolic leucyl aminopeptidase (EC 3.4.11.1) as the major cysteinylglycine-hydrolysing activity in rat liver.
Jösch, C; Klotz, LO; Sies, H, 2003
)
1.99

Actions

ExcerptReferenceRelevance
"Only cysteinylglycine was lower than controls (P < 0.001) when selenium > 1.06 micromol/l."( Oxidative stress in mothers who have conceived fetus with neural tube defects: the role of aminothiols and selenium.
Besalduch, A; Gibert, MJ; Martín, I; Noguera, A; Obrador, A; Pintos, C, 2004
)
0.78

Toxicity

ExcerptReferenceRelevance
" Criteria based on neurological indices, mortality, and weight loss indicated that the cys-gly complex of CH3Hg was significantly less toxic than CH3Hg or the other complexes."( Toxicity, distribution, and elimination of thiol complexes of methylmercury after intracerebral injection.
Balthrop, JE; Braddon-Galloway, S; Fair, PH; Wade, JL, 1986
)
0.27
" In cysteine-free medium, all 1:1 Hg(II):thiol complexes were as toxic as uncomplexed Hg(II), and almost all 1:2 Hg(II):thiol complexes protected at > or =20 microM Hg, except albumin, which protected at < or =20 microM Hg."( Glutathione, albumin, cysteine, and cys-gly effects on toxicity and accumulation of mercuric chloride in LLC-PK1 cells.
Ayala-Fierro, F; Barber, DS; Carter, DE; Divine, KK, 1999
)
0.3
" To elucidate direct toxic effects of isothiocyanates (ITCs), BITC, AITC, or BITC-metabolites conjugated either with glutathione, cysteinylglycine, cysteine, or mercapturic acid were intravesically instilled into female F344 rats."( Toxic effects of benzyl and allyl isothiocyanates and benzyl-isoform specific metabolites in the urinary bladder after a single intravesical application to rats.
Hirose, M; Masutomi, N; Niho, N; Shibutani, M; Takahashi, N; Toyoda, K; Uneyama, C,
)
0.34

Bioavailability

ExcerptReferenceRelevance
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
" In vitro GSH transport assays indicated that GSH is poorly absorbed (<20%)."( Glutathione-enriched baker's yeast: production, bioaccessibility and intestinal transport assays.
Calatayud, M; Devesa, V; Manzoni, M; Musatti, A; Rollini, M; Vélez, D, 2014
)
0.4
" Although GSH present in enriched yeasts is poorly absorbed by intestinal cells, this biomass showed an intestinal local protective effect, improving cells viability when a simulated oxidative stress was applied."( Glutathione-enriched baker's yeast: production, bioaccessibility and intestinal transport assays.
Calatayud, M; Devesa, V; Manzoni, M; Musatti, A; Rollini, M; Vélez, D, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" Electrospray ionization-liquid chromatography/mass spectrometry analyses of bile samples from rats dosed with either efavirenz or with 8-OH efavirenz revealed three polar metabolites, M9, M12, and M13, with pseudomolecular ions [M-H](-) at m/z 733, 602, and 749, respectively."( Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz.
Chen, H; Christ, DD; Gan, LS; Mutlib, AE; Nemeth, G, 1999
)
0.3
" Low levodopa dosing and antioxidants in the rotigotine patch matrix prevented cysteinyl-glycine fall."( Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Herrman, L; Kinkel, M; Muhlack, S; Müller, T, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dipeptide zwitterionAny peptide zwitterion comprising two amino acid residues. Major structure at pH 7.3.
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Glutathione Metabolism1121
Glutathione Synthetase Deficiency1121
5-Oxoprolinuria1121
gamma-Glutamyltransferase Deficiency1121
5-Oxoprolinase Deficiency1121
gamma-Glutamyltranspeptidase Deficiency1121
Oxidative stress and redox pathway019
Relationship between glutathione and NADPH036
Glutathione and one-carbon metabolism010
Glutathione metabolism013
Gamma-glutamyl cycle for the biosynthesis and degradation of glutathione, including diseases69

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Homo sapiens (human)Ki200.00000.01472.50379.2000AID92023
Glutamate receptor 2Homo sapiens (human)Ki200.00000.01681.27725.0000AID92023
Glutamate receptor 3Homo sapiens (human)Ki200.00000.02060.53222.2000AID92023
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)Ki200.00000.00380.79754.1000AID92023
Solute carrier family 15 member 1Homo sapiens (human)Ki200.00000.18003.39339.8000AID238858; AID92023
Glutamate receptor 4Homo sapiens (human)Ki200.00000.04001.23358.8500AID92023
Solute carrier family 15 member 2Homo sapiens (human)Ki28.92010.79434.22108.0000AID612540
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (53)

Processvia Protein(s)Taxonomy
regulation of receptor recyclingGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synapse assemblyGlutamate receptor 1Homo sapiens (human)
long-term memoryGlutamate receptor 1Homo sapiens (human)
response to xenobiotic stimulusGlutamate receptor 1Homo sapiens (human)
response to lithium ionGlutamate receptor 1Homo sapiens (human)
positive regulation of gene expressionGlutamate receptor 1Homo sapiens (human)
neuronal action potentialGlutamate receptor 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 1Homo sapiens (human)
spinal cord developmentGlutamate receptor 1Homo sapiens (human)
cerebral cortex developmentGlutamate receptor 1Homo sapiens (human)
receptor internalizationGlutamate receptor 1Homo sapiens (human)
response to estradiolGlutamate receptor 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 1Homo sapiens (human)
response to cocaineGlutamate receptor 1Homo sapiens (human)
positive regulation of membrane potentialGlutamate receptor 1Homo sapiens (human)
response to arsenic-containing substanceGlutamate receptor 1Homo sapiens (human)
response to electrical stimulusGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 1Homo sapiens (human)
long-term synaptic depressionGlutamate receptor 1Homo sapiens (human)
response to fungicideGlutamate receptor 1Homo sapiens (human)
cellular response to amino acid stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to ammonium ionGlutamate receptor 1Homo sapiens (human)
cellular response to dsRNAGlutamate receptor 1Homo sapiens (human)
cellular response to peptide hormone stimulusGlutamate receptor 1Homo sapiens (human)
cellular response to amine stimulusGlutamate receptor 1Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusGlutamate receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 1Homo sapiens (human)
signal transductionGlutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 2Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 2Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor 2Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 2Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
calcium-mediated signalingGlutamate receptor 3Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 3Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 3Homo sapiens (human)
protein homotetramerizationGlutamate receptor 3Homo sapiens (human)
protein heterotetramerizationGlutamate receptor 3Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
long-term synaptic potentiationGlutamate receptor 3Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 3Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor 4Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processGlutamate receptor 4Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor 4Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor 4Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor 4Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
amyloid-beta bindingGlutamate receptor 1Homo sapiens (human)
G-protein alpha-subunit bindingGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
protein bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor activityGlutamate receptor 1Homo sapiens (human)
adenylate cyclase bindingGlutamate receptor 1Homo sapiens (human)
immunoglobulin bindingGlutamate receptor 1Homo sapiens (human)
protein kinase bindingGlutamate receptor 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 1Homo sapiens (human)
PDZ domain bindingGlutamate receptor 1Homo sapiens (human)
small GTPase bindingGlutamate receptor 1Homo sapiens (human)
myosin V bindingGlutamate receptor 1Homo sapiens (human)
G-protein beta-subunit bindingGlutamate receptor 1Homo sapiens (human)
beta-2 adrenergic receptor bindingGlutamate receptor 1Homo sapiens (human)
glutamate receptor bindingGlutamate receptor 1Homo sapiens (human)
identical protein bindingGlutamate receptor 1Homo sapiens (human)
protein kinase A bindingGlutamate receptor 1Homo sapiens (human)
scaffold protein bindingGlutamate receptor 1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 2Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 2Homo sapiens (human)
protein bindingGlutamate receptor 2Homo sapiens (human)
ligand-gated monoatomic cation channel activityGlutamate receptor 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 3Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 3Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor 3Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 3Homo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor 4Homo sapiens (human)
glutamate-gated receptor activityGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor activityGlutamate receptor 4Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor 4Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (42)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
cell-cell junctionGlutamate receptor 1Homo sapiens (human)
cell surfaceGlutamate receptor 1Homo sapiens (human)
ER to Golgi transport vesicle membraneGlutamate receptor 1Homo sapiens (human)
postsynaptic densityGlutamate receptor 1Homo sapiens (human)
dendriteGlutamate receptor 1Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 1Homo sapiens (human)
synaptic vesicle membraneGlutamate receptor 1Homo sapiens (human)
neuromuscular junctionGlutamate receptor 1Homo sapiens (human)
early endosome membraneGlutamate receptor 1Homo sapiens (human)
dendritic spine membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell body membraneGlutamate receptor 1Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneGlutamate receptor 1Homo sapiens (human)
neuronal cell bodyGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
dendritic shaftGlutamate receptor 1Homo sapiens (human)
axonal spineGlutamate receptor 1Homo sapiens (human)
neuron spineGlutamate receptor 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor 1Homo sapiens (human)
presynaptic active zone membraneGlutamate receptor 1Homo sapiens (human)
recycling endosomeGlutamate receptor 1Homo sapiens (human)
recycling endosome membraneGlutamate receptor 1Homo sapiens (human)
excitatory synapseGlutamate receptor 1Homo sapiens (human)
synaptic membraneGlutamate receptor 1Homo sapiens (human)
presynapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
glutamatergic synapseGlutamate receptor 1Homo sapiens (human)
postsynaptic density, intracellular componentGlutamate receptor 1Homo sapiens (human)
perisynaptic spaceGlutamate receptor 1Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Homo sapiens (human)
dendritic spineGlutamate receptor 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
external side of plasma membraneGlutamate receptor 2Homo sapiens (human)
postsynaptic densityGlutamate receptor 2Homo sapiens (human)
dendriteGlutamate receptor 2Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 2Homo sapiens (human)
asymmetric synapseGlutamate receptor 2Homo sapiens (human)
neuronal cell bodyGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
excitatory synapseGlutamate receptor 2Homo sapiens (human)
postsynapseGlutamate receptor 2Homo sapiens (human)
postsynaptic endocytic zoneGlutamate receptor 2Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 2Homo sapiens (human)
dendritic spineGlutamate receptor 2Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 2Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic membraneGlutamate receptor 3Homo sapiens (human)
parallel fiber to Purkinje cell synapseGlutamate receptor 3Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 3Homo sapiens (human)
plasma membraneGlutamate receptor 3Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 3Homo sapiens (human)
dendritic spineGlutamate receptor 3Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendriteGlutamate receptor 4Homo sapiens (human)
endocytic vesicle membraneGlutamate receptor 4Homo sapiens (human)
neuronal cell bodyGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
extracellular vesicleGlutamate receptor 4Homo sapiens (human)
AMPA glutamate receptor complexGlutamate receptor 4Homo sapiens (human)
postsynaptic density membraneGlutamate receptor 4Homo sapiens (human)
plasma membraneGlutamate receptor 4Homo sapiens (human)
dendritic spineGlutamate receptor 4Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID390209Antioxidant activity assessed as reducing capacity of DTNB at 20 uM after 30 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID92023Inhibition constant (Ki) for human intestinal peptide carrier2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H+/peptide cotransporter PEPT1.
AID390216Induction of ascorbic acid oxidation preincubated for 3 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390217Induction of ascorbic acid oxidation preincubated for 30 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID695876Cytotoxicity against drug-resistant human KBV1 cells expressing P-gp incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID390215Antioxidant activity assessed as reducing capacity of Iodine solution at 0.25 mM after 120 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID678975TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-24, Volume: 276, Issue:2
Cloning and characterization of the gene encoding the mouse peptide transporter PEPT2.
AID390213Antioxidant activity assessed as reducing capacity of DTNB at 20 uM after 60 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390212Antioxidant activity assessed as DPPH radical scavenging activity at 36 uM after 30 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390219Induction of ascorbic acid oxidation preincubated for 300 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID500816Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID695851Resistance index, ratio of IC50 for human KB-3-1 cells to IC50 for drug-resistant human KBV1 cells expressing P-gp2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID390214Antioxidant activity assessed as reducing capacity of Iodine solution at 0.25 mM after 60 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390226Antioxidant activity assessed as ABTS radical scavenging activity at 4 uM after 3 mins in presence of Cu2+2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390218Induction of ascorbic acid oxidation preincubated for 60 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390211Antioxidant activity assessed as ABTS radical scavenging activity at 4 uM after 30 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390227Antioxidant activity assessed as DPPH radical scavenging activity at 36 uM after 3 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390225Antioxidant activity assessed as DPPH radical scavenging activity after 40 mins in absence of Cu2+2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390222Effect on CU2+-mediated superoxide-dependent lucigenin reduction by chemiluminescence assay at 10 to 30 uM2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID695877Cytotoxicity against human KB-3-1 cells incubated for 72 hrs by MTT assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin.
AID390210Antioxidant activity assessed as reducing capacity of Iodine solution at 0.25mM after 30 mins in presence of Cu2++2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390220Effect on CU2+-mediated superoxide-dependent cytochrome c reduction at 10 to 30 uM2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
AID390224Antioxidant activity assessed as ABTS radical scavenging activity after 30 mins in absence of Cu2+2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Double edge redox-implications for the interaction between endogenous thiols and copper ions: In vitro studies.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (232)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (7.76)18.7374
1990's51 (21.98)18.2507
2000's93 (40.09)29.6817
2010's61 (26.29)24.3611
2020's9 (3.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.49 (24.57)
Research Supply Index5.56 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index43.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (4.86%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other235 (95.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]